Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease

Abstract

Spanish

French

Objective:

To review certolizumab pegol for the treatment of moderate-to-severe Crohn's disease (CD).

Data Sources:

Clinical studies were identified through MEDLINE (1966–October 1, 2009), bibliographies of articles, International Pharmaceutical Abstracts, clinicaltrials.gov, fda.gov, and New Drug Approval documents (www.accessdata.fda.gov). Search terms were CDP 870, certolizumab pegol, Cimzia, Crohn's disease, and inflammatory bowel disease.

Study Selection and Data Extraction:

Human studies describing pharmacology, pharmacokinetics, efficacy, and safety of certolizumab pegol were identified. Phase 2 and Phase 3 randomized controlled trials and observational studies were reviewed, with emphasis given to Phase 2 and Phase 3 trials.

Data Synthesis:

Certolizumab pegol is a tumor necrosis factor-alfa (TNF-α) antagonist, approved for the treatment of moderate-to-severe CD that is failing conventional therapy. It is an antigen-binding fragment (Fab') portion of an immunoglobulin G antibody attached to a polyethylene glycol moiety. In 2 Phase 3 randomized, placebo-controlled trials, certolizumab pegol was effective in inducing clinical response compared with placebo. Common adverse effects during clinical trials were upper respiratory tract infection, urinary tract infection, and arthralgia. Serious infection occurred in 3% of patients. The 4 published controlled trials for the use of certolizumab pegol in the treatment of CD share similar limitations with other studies of TNF-α antagonists including high placebo response, natural course of disease fluctuation, and the use of Crohn's Disease Activity Index to assess outcomes. However, certolizumab pegol is an effective agent for adults with moderate-to-severe CD with less than optimal response to conventional therapy. Long-term efficacy and safety data are unavailable. Certolizumab pegol and adalimumab, unlike infliximab, can be self-administered.

Conclusions:

With similarity in cost and the lack of head-to-head comparisons, patient and physician preference may determine choice of TNF-α antagonist.

Keywords

certolizumab pegol Crohn's disease inflammatory bowel disease TNF-α antagonist

Get full access to this article

View all access options for this article.

References

Kappelman

, Rifas-Shiman

, Kleinman

. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1383–4.

Loftus

Jr , Schoenfield

, Sandborn

. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16:51–60.

Lewis

. Anti-TNF antibodies for Crohn's disease–-in pursuit of the perfect clinical trial. N Engl J Med 2007; 357:296–8.

Bennell

, Lapidus

, Hellers

. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38–45.

, Cabanilla

, Wu

. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 23:319–28.

Panés

, Gomolló

, Taxonera

. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007; 67:2311–37.

Product information. Remicade (infliximab). Horsham, PA: Centocor, September 2008.

Product information. Humira (adalimumab). St. Laurent, Canada: Abbott Laboratories, February 2009.

Product information. Cimzia (certolizumab). Smyrna, GA: UCB Pharmaceuticals, April 2008.

10.

UCB. Belgium; c2007–2009 [updated 2009 May 14]. www.ucb.com/news/newsdetail?det=1314787 (accessed 2009 May 14).

11.

Veronese

, Mero

. The impact of PEGylation on biological therapies. BioDrugs 2008; 22:315–29.

12.

Bourne

, Fossati

, Nesbitt

. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008; 22:331–7.

13.

Sandborn

, Hanauer

, Katz

. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088–94.

14.

Nesbitt

, Henry

. High affinity and potency of the pegylated fab' fragment CDP870: a direct comparison with other anti-TNF agents (abstract 781). Am J Gastroenterol 2004; 99:S253.

15.

Hehlgans

, Pfeffer

. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115:1–20.

16.

Tracey

, Klareskog

, Sasso

. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244–79.

17.

Schreiber

, Nikolaus

, Hampe

. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353:459–61.

18.

Braegger

, Nicholls

, Murch

. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89–91.

19.

Nesbitt

, Fossati

, Bergin

. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323–32.

20.

ten Hove

, van Montfrans

, Peppelenbosch

. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206–11.

21.

Kirman

, Whelan

, Nielsen

. Infliximab: mechanism of action beyond TNF alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16:639–41.

22.

Tang

, Persky

, Hochhaus

. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004; 93:2184–204.

23.

Mahmood

, Green

. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005; 44:331–47.

24.

Baker

, Stephens

. Investigation of the pharmacokinetic properties of certolizumab pegol, an anti-TNF agent. Am J Gastroenterol 2006; 101:1117.

25.

Winter

, Wright

, Ghosh

. Intravenous CDP870, a pegylated Fab fragment of a humanized antitumor necrosis factor antibody, in patients with moderate to severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004; 20:1337–46.

26.

Schreiber

, Rutgeerts

, Fedorak

. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807–18.

27.

Sandborn

, Feagan

, Stoinov

. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228–38.

28.

Schreiber

, Khaliq-Kareemi

, Lawrance

. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239–50.

29.

Best

, Becktel

, Singleton

. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439–44.

30.

, Lichenstein

, Krok

. A meta-analysis of the placebo response rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126:1257–69.

31.

Gallahan

. Placebo is becoming more effective in Crohn's disease (abstract P675). Presented at: American College of Gastroenterology Scientific Meeting, October 2008.

32.

Colombel

, Hanauer

, Sandborn

. Certolizumab pegol administered subcutaneously is effective in anti-TNF naïve patients and in patients previously treated with infliximab (abstract). Gut 2006; 55(suppl V):A21.

33.

Colombel

, Hebuterne

. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Am J Gastroenterol 2008; 103:P13.

34.

Vermeire

, Abreu

, D'Haens

. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction results of the WELCOME study (abstract P-0066). Presented at 2008 Advances in Inflammatory Bowel Disease Clinical and Research Conference.

35.

Danese

, Mocciaro

, Guidi

. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use (letter). Inflamm Bowel Dis 2008; 14:1168–70.

36.

Vermeire

, Collin

, Mitchev

. Certolizumab pegol in patients with Crohn's disease who failed treatment with other anti-TNFs: data from a compassionate use program (abstract P-065). Presented at 2007 Advances in Inflammatory Bowel Disease Clinical and Research Conference.

37.

FDA: TNF blockers increase risk of lymphoma, other cancers. AAP News 2009: aapnews.20090807-1 (accessed 2009 Aug 5).

38.

Sandborn

, Lichenstein

, Schreiber

. The long-term, 30-month, efficacy and tolerability of certolizumab pegol therapy for Crohn's disease (abstract P-0061). Presented at 2008 Advances in Inflammatory Bowel Disease Clinical and Research Conference.

39.

Colombel

, Schreiber

, Rutgeerts

. Long-term safety of certolizumab pegol in Crohn's disease: integrated safety findings on serious adverse events of special interest (abstract P-0019). Presented at 2008 Advances in Inflammatory Bowel Disease Clinical and Research Conference.

40.

Salliot

, Dougados

, Gossec

. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25–32.

41.

Wilkinson

. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 35:2211–21.

42.

Abdel-Razzak

, Loyer

, Fautrel

. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44:707–15.

43.

Drug topics red book. Montvale, NJ: Thomson Healthcare, 2008.

44.

Zisman

, Cohen

. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10:185–94.

45.

Feagan

, Bala

, Yan

. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005; 39:390–5.

46.

Feagan

, Tan

, Malone

. Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease (abstract). Inflamm Bowel Dis 2008; 14(suppl 3):S33.

47.

Danese

, Stefanelli

, Omodei

. Successful treatment of fistulizing Crohn's disease with certolizumab pegol. Inflamm Bowel Dis 2008; 14:292–3.

48.

Schreiber

, Lawrence

, Thomsen

. Cimzia (certolizumab pegol) is effective in the treatment of Crohn's disease patients with open fistulas (abstract). Inflamm Bowel Dis 2008; 14(suppl 3):S1.

49.

Furst

. Certolizumab pegol–-what role does this new TNF inhibitor have in the treatment of RA? Nat Clin Pract Rheumatol 2009; 5:134–5.

50.

Smolen

, Landewe

, Mease

. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis 2009; 68:799–804.

51.

Keystone

, Heijde

, Mason

Jr . Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319–29.

52.

Fleischmann

, Vencovsky

, van Vollenhoven

. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805–11.

53.

Sandborn

, Hanauer

, Rutgeerts

. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECISE 4 results (abstract). Gastroenterology 2007; 132(4 suppl 2):A505.